Oxytocin for Frontotemporal Dementia: a Randomized Dose-finding Study of Safety and Tolerability

Overview

Journal Neurology

Specialty Neurology

Date 2014 Dec 16

PMID 25503617

Citations 44

Authors

Elizabeth C Finger

Julia MacKinley

Mervin Blair

Lindsay D Oliver

Sarah Jesso

Maria C Tartaglia

Michael Borrie

Jennie Wells

Isabel Dziobek

Stephen Pasternak

Derek G V Mitchell

Katherine Rankin

Andrew Kertesz

Adam Boxer

Affiliations

Soon will be listed here.

Abstract

Objective: To determine the safety and tolerability of 3 doses of intranasal oxytocin (Syntocinon; Novartis, Bern, Switzerland) administered to patients with frontotemporal dementia (FTD).

Methods: We conducted a randomized, parallel-group, double-blind, placebo-controlled study using a dose-escalation design to test 3 clinically feasible doses of intranasal oxytocin (24, 48, or 72 IU) administered twice daily for 1 week to 23 patients with behavioral variant FTD or semantic dementia (clinicaltrials.gov registration number NCT01386333). Primary outcome measures were safety and tolerability at each dose. Secondary measures explored efficacy across the combined oxytocin vs placebo groups and examined potential dose-related effects.

Results: All 3 doses of intranasal oxytocin were safe and well tolerated.

Conclusions: A multicenter trial is warranted to determine the therapeutic efficacy of long-term intranasal oxytocin for behavioral symptoms in FTD.

Classification Of Evidence: This study provides Class I evidence that for patients with FTD, intranasal oxytocin is not significantly associated with adverse events or significant changes in the overall neuropsychiatric inventory.

Citing Articles

Birth Rate as a Determinant of Dementia Incidence: A Comprehensive Global Analysis.

You W Am J Alzheimers Dis Other Demen. 2025; 40:15333175241287677.

PMID: 39878193 PMC: 11775964. DOI: 10.1177/15333175241287677.

Expert opinions on pharmacological symptomatic treatment of behavioral symptoms in frontotemporal dementia: A survey of the Neuropsychiatric International Consortium on Frontotemporal Dementia (NIC-FTD).

van Paassen D, Hartog L, de Boer S, Vijverberg E, Ducharme S, Pijnenburg Y Eur J Neurol. 2024; 32(1):e16537.

PMID: 39607834 PMC: 11625954. DOI: 10.1111/ene.16537.

Oxytocin in old age psychiatry: A systematic review of the safety of using intranasal oxytocin in older adults.

Sawares A, Olver J, Morcos M, Norman T Australas Psychiatry. 2024; 33(1):33-44.

PMID: 39474844 PMC: 11804147. DOI: 10.1177/10398562241291335.

Frontotemporal lobar degeneration.

Grossman M, Seeley W, Boxer A, Hillis A, Knopman D, Ljubenov P Nat Rev Dis Primers. 2023; 9(1):40.

PMID: 37563165 DOI: 10.1038/s41572-023-00447-0.

A Systematic Review of Pharmacological Interventions for Apathy in Aging Neurocognitive Disorders.

Theleritis C, Siarkos K, Politis A, Smyrnis N, Papageorgiou C, Politis A Brain Sci. 2023; 13(7).

PMID: 37508993 PMC: 10377475. DOI: 10.3390/brainsci13071061.

References

Diodati D, Cyn-Ang L, Kertesz A, Finger E . Pathologic evaluation of the supraoptic and paraventricular nuclei in dementia. Can J Neurol Sci. 2012; 39(2):213-9. DOI: 10.1017/s0317167100013251. View

Storer B . Design and analysis of phase I clinical trials. Biometrics. 1989; 45(3):925-37. View

Neumann I, Maloumby R, Beiderbeck D, Lukas M, Landgraf R . Increased brain and plasma oxytocin after nasal and peripheral administration in rats and mice. Psychoneuroendocrinology. 2013; 38(10):1985-93. DOI: 10.1016/j.psyneuen.2013.03.003. View

Diehl-Schmid J, Schmidt E, Nunnemann S, Riedl L, Kurz A, Forstl H . Caregiver burden and needs in frontotemporal dementia. J Geriatr Psychiatry Neurol. 2013; 26(4):221-9. DOI: 10.1177/0891988713498467. View

Striepens N, Kendrick K, Hanking V, Landgraf R, Wullner U, Maier W . Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal administration in humans. Sci Rep. 2013; 3:3440. PMC: 3853684. DOI: 10.1038/srep03440. View

Kertesz A, Davidson W, Fox H . Frontal behavioral inventory: diagnostic criteria for frontal lobe dementia. Can J Neurol Sci. 1997; 24(1):29-36. DOI: 10.1017/s0317167100021053. View

Kosfeld M, Heinrichs M, Zak P, Fischbacher U, Fehr E . Oxytocin increases trust in humans. Nature. 2005; 435(7042):673-6. DOI: 10.1038/nature03701. View

Cummings J . The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997; 48(5 Suppl 6):S10-6. DOI: 10.1212/wnl.48.5_suppl_6.10s. View

Neary D, Snowden J, Gustafson L, Passant U, Stuss D, Black S . Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998; 51(6):1546-54. DOI: 10.1212/wnl.51.6.1546. View

10.

Rankin K, Kramer J, Miller B . Patterns of cognitive and emotional empathy in frontotemporal lobar degeneration. Cogn Behav Neurol. 2005; 18(1):28-36. DOI: 10.1097/01.wnn.0000152225.05377.ab. View

11.

Bosch O, Meddle S, Beiderbeck D, Douglas A, Neumann I . Brain oxytocin correlates with maternal aggression: link to anxiety. J Neurosci. 2005; 25(29):6807-15. PMC: 6725361. DOI: 10.1523/JNEUROSCI.1342-05.2005. View

12.

Hollander E, Bartz J, Chaplin W, Phillips A, Sumner J, Soorya L . Oxytocin increases retention of social cognition in autism. Biol Psychiatry. 2006; 61(4):498-503. DOI: 10.1016/j.biopsych.2006.05.030. View

13.

Dziobek I, Rogers K, Fleck S, Bahnemann M, Heekeren H, Wolf O . Dissociation of cognitive and emotional empathy in adults with Asperger syndrome using the Multifaceted Empathy Test (MET). J Autism Dev Disord. 2007; 38(3):464-73. DOI: 10.1007/s10803-007-0486-x. View

14.

Born J, Lange T, Kern W, McGregor G, Bickel U, Fehm H . Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci. 2002; 5(6):514-6. DOI: 10.1038/nn849. View

15.

Knopman D, Kramer J, Boeve B, Caselli R, Graff-Radford N, Mendez M . Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain. 2008; 131(Pt 11):2957-68. PMC: 2725027. DOI: 10.1093/brain/awn234. View

16.

Donaldson Z, Young L . Oxytocin, vasopressin, and the neurogenetics of sociality. Science. 2008; 322(5903):900-4. DOI: 10.1126/science.1158668. View

17.

Marsh A, Yu H, Pine D, Blair R . Oxytocin improves specific recognition of positive facial expressions. Psychopharmacology (Berl). 2010; 209(3):225-32. DOI: 10.1007/s00213-010-1780-4. View

18.

Hurlemann R, Patin A, Onur O, Cohen M, Baumgartner T, Metzler S . Oxytocin enhances amygdala-dependent, socially reinforced learning and emotional empathy in humans. J Neurosci. 2010; 30(14):4999-5007. PMC: 6632777. DOI: 10.1523/JNEUROSCI.5538-09.2010. View

19.

Mioshi E, Hsieh S, Savage S, Hornberger M, Hodges J . Clinical staging and disease progression in frontotemporal dementia. Neurology. 2010; 74(20):1591-7. DOI: 10.1212/WNL.0b013e3181e04070. View

20.

Gamer M, Zurowski B, Buchel C . Different amygdala subregions mediate valence-related and attentional effects of oxytocin in humans. Proc Natl Acad Sci U S A. 2010; 107(20):9400-5. PMC: 2889107. DOI: 10.1073/pnas.1000985107. View